Lagevrio (molnupiravir) added $3.2 billion to Merck's top line of $15.9 billion, but even without the drug sales would have risen 19% thanks to a strong performance from cancer immunotherapy ...
Paxlovid significantly shortened the time to symptom relief (median, 13 vs 15 days; hazard ratio [HR], 1.27) and resolution ...
The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the ...
The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback